Additionally, the 36-month beta value for CARA is 0.86. There are mixed opinions on the stock, with 7 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The average price predicted by analysts for CARA is $17.63, which is $14.58 above the current price. The public float for CARA is 45.03M and currently, short sellers hold a 11.13% ratio of that float. The average trading volume of CARA on May 26, 2023 was 752.69K shares.
25-cent Stock Takes $11T Commodities Sector Digital
One brilliantly-run technology firm has successfully partnered with some of the largest players in the industry to bring a first-of-its-kind digital solution to the global commodities supply chain sector. Best of all, this upstart technology firm is currently trading undiscovered — below 25-cents per share — so very, very few investors know about it yet! For investors… it's an early-stage opportunity in a company that's bringing the US$11T global commodities sector straight into the 21st century.
All the details are in the FREE online report you can get here.
CARA) stock’s latest price update
Cara Therapeutics Inc. (NASDAQ: CARA)’s stock price has dropped by -6.55 in relation to previous closing price of 3.51. Nevertheless, the company has seen a loss of -14.81% in its stock price over the last five trading days.
CARA’s Market Performance
Cara Therapeutics Inc. (CARA) has experienced a -14.81% fall in stock performance for the past week, with a -18.00% drop in the past month, and a -67.30% drop in the past quarter. The volatility ratio for the week is 5.64%, and the volatility levels for the past 30 days are at 5.73% for CARA. The simple moving average for the past 20 days is -19.52% for CARA’s stock, with a -63.44% simple moving average for the past 200 days.
CARA Trading at -26.62% from the 50-Day Moving Average
After a stumble in the market that brought CARA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -74.73% of loss for the given period.
Volatility was left at 5.73%, however, over the last 30 days, the volatility rate increased by 5.64%, as shares sank -19.01% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -43.06% lower at present.
During the last 5 trading sessions, CARA fell by -14.81%, which changed the moving average for the period of 200-days by -72.23% in comparison to the 20-day moving average, which settled at $4.04. In addition, Cara Therapeutics Inc. saw -69.46% in overturn over a single year, with a tendency to cut further losses.
Reports are indicating that there were more than several insider trading activities at CARA starting from Posner Christopher, who sale 3,869 shares at the price of $4.40 back on May 05. After this action, Posner Christopher now owns 172,514 shares of Cara Therapeutics Inc., valued at $17,024 using the latest closing price.
Menzaghi Frederique Ph.D., the Chief Scientific Off,SVP-R&D of Cara Therapeutics Inc., sale 2,733 shares at $4.91 during a trade that took place back on Apr 04, which means that Menzaghi Frederique Ph.D. is holding 156,740 shares at $13,419 based on the most recent closing price.
Stock Fundamentals for CARA
Current profitability levels for the company are sitting at:
- -209.08 for the present operating margin
- +82.05 for the gross margin
The net margin for Cara Therapeutics Inc. stands at -204.16. The total capital return value is set at -44.67, while invested capital returns managed to touch -44.03. Equity return is now at value -49.30, with -43.50 for asset returns.
Based on Cara Therapeutics Inc. (CARA), the company’s capital structure generated 1.21 points at debt to equity in total, while total debt to capital is 1.19.
When we switch over and look at the enterprise to sales, we see a ratio of 1.05, with the company’s debt to enterprise value settled at 0.00. The receivables turnover for the company is 14.94 and the total asset turnover is 0.20. The liquidity ratio also appears to be rather interesting for investors as it stands at 7.20.
In conclusion, Cara Therapeutics Inc. (CARA) has seen bad performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.